Neuronoff raises $4.5 million to bring needle-based chronic pain treatment to market
Image: Neuronoff
Cleveland-based Neuronoff has closed an oversubscribed $4.5 million financing round to accelerate the FDA clearance and 2026 commercial launch of its Injectrode® platform, a minimally invasive, drug-free treatment for chronic pain.
Why it matters
Chronic pain affects more than 50 million Americans, yet most neuromodulation therapies today require surgical incisions, implanted hardware, and high costs that limit access. Neuronoff’s approach—using a 1mm injectable electrode delivered through an 18-gauge needle—could offer a simpler, lower-cost alternative that sidesteps opioids and surgery altogether.
The details
The new funding will help Neuronoff scale production to 1,000 units annually and prepare for a limited U.S. launch in 2026 targeting pain specialists, spinal surgeons, and podiatrists.
The Injectrode platform eliminates the need for one- to two-inch incisions common in traditional neurostimulation, reducing visible scarring and recovery time.
The company estimates it can cut payer costs by 50% or more, potentially enabling earlier insurance approvals and faster access for patients.
What they’re saying
“This funding validates our investors’ confidence in bringing elegant, needle-based neuromodulation to future patients,” said Manfred Franke, CEO of Neuronoff. “We aim to offer effective chronic pain treatments without opioids, without surgery, and without scars.”
Investor perspective
“The neuromodulation sector is prime for an advancement in lead development,” said Andrew Zeringue, managing member of MedTech Angels, which participated in the round. “Physicians need a better way to deliver these new electrical waveforms to the various anatomical targets.”
Clinical progress
Neuronoff’s first-in-human trial for chronic lower back pain showed no serious adverse events and demonstrated consistent device performance over the implant period. The company believes its core technology could extend into other therapeutic areas, including autonomic, cardiac, bladder, and inflammatory disorders.
What’s next
Neuronoff has also formed a wholly owned subsidiary to pursue an undisclosed indication affecting roughly 16 million U.S. adults. The company plans to share more details at the North American Neuromodulation Society Annual Meeting in January 2026 in Las Vegas.
The big picture
Neuronoff’s innovation underscores Ohio’s growing strength in medical technology and bioengineering, joining a cluster of startups and research institutions in Cleveland working at the intersection of advanced materials, minimally invasive procedures, and AI-powered diagnostics.